Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

Extracellular vesicles: emerging therapeutic agents for liver fibrosis

Chiabotto G., Semnani A., Ceccotti E., Bruno S.

Narrative Review on Scar, published in Extracell Vesicles Circ Nucl Acids (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Extracell Vesicles Circ Nucl Acids (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40852596
PMCID
PMC12367467
DOI
10.20517/evcna.2025.08
Citations
3

Abstract (original English)

Liver fibrosis is a progressive condition characterized by excessive scar tissue buildup, leading to impaired liver function and potentially cirrhosis. Despite advancements in treatment strategies, effective anti-fibrotic therapies remain an urgent unmet need. Recent research has identified extracellular vesicles (EVs) as promising therapeutic agents due to their ability to mediate intercellular communication and regulate key fibrotic pathways. This review aims to provide a comprehensive overview of the therapeutic potential of EVs in different in vitro and in vivo models of hepatic fibrosis, focusing on their natural effects and recent advancements in their engineering for enhanced efficacy. EVs can be derived from various cellular sources, including mesenchymal stromal cells (MSCs) and liver-resident cells. Biological materials, including serum, breast milk, bacteria, and plants, also serve as EV sources. Among these, MSC-EVs stand out for their therapeutic potential, which can be significantly enhanced through preconditioning with inflammatory signals, pharmacological agents, or genetic engineering to improve EV quality and efficacy. Engineering techniques have further expanded EV applications, enabling their use as precise and effective drug-delivery vehicles. Approaches such as loading EVs with pharmacological compounds, designing customized EVs, and creating EV-liposome h

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research